Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis.
Infliximab is a chimerical monoclonal antibody currently used in the treatment of various inflammatory diseases. Lupus-like syndrome is a rarely reported adverse event, and generally observed in rheumatoid arthritis cases. We hereby define and describe a case of a lupus-like syndrome, which developed following the 4th infliximab infusion in a 62-year-old patient with ankylosing spondylitis (AS). As far as we acknowledge, the present case is the third AS case with infliximab-induced lupus.
Bodur
Hatice
H
Department of Physical Medicine and Rehabilitation, Ankara Numune Education and Research Hospital, Ankara, Turkey. haticebodur@gmail.com
Eser
Filiz
F
Konca
Sefika
S
Arikan
Serpil
S
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000925:Anticoagulants / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects*; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D018501:Antirheumatic Agents; D017984:Enoxaparin; D000069285:Infliximab; D008775:Methylprednisolone